Bolt Biotherapeutics Inc expected to post a loss of 56 cents a share - Earnings Preview

Bolt Biotherapeutics

05/11/2022 03:03

* Bolt Biotherapeutics Inc  BOLT.OQ   BOLT.O  is expected
to show
a rise in quarterly revenue when it reports  results on November
7 (estimated). 
    * The Redwood City California-based  company is expected to
report
 a 30.9% increase in revenue to $984.6 thousand from $752
thousand a year ago, according to the mean estimate from 5
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Bolt
Biotherapeutics Inc
is for a loss of 56 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Bolt
Biotherapeutics Inc is $7.5​, above​ its last closing price
of $1.34. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.69       -0.68      -0.61     Beat    10
 Mar. 31 2022  -0.72       -0.72      -0.64     Beat    10.8
 Dec. 31 2021  -1.43       -0.82      -0.73     Beat    10.8​
 Sep. 30 2021  -0.66       -0.65      -0.63     Beat    3.4
 ​​Jun.        -0.43       -0.43      -0.64     Missed  -48.8
 30 2021                                                
 Mar. 31 2021  -0.60       -0.60      -1.14     Missed  -90​
 Dec. 31 2020  -1.80       -1.80      -14.58    Missed  -708.9
 This summary was machine generated November 5 at 03:03 GMT.  All
figures in US dollars  unless otherwise stated